Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (630)	4/3/1998 10:55:00 PM
From: Robohogs	Respond to of 965

Merck drug is Aggrastat and has only been tested for a narrow indication, less broad even than Reopro. By the way guys, Reopro has been approved for unstable angina patients going immediately to angioplasty (this is the escape valve to off-label use). But Reopro is not approved for all unstable angina patient use. Avakine does go before panel in late May. No head to heads yet with either CORR or Merck drugs. All indications would be that Reopro is better although testing methodologies and endpoints have been different to date - for Christ sake, the panel didn't even want to approve Aggrastat so broadly. We'll be up 2-5 next week IMHO.